Legal Representation
Attorney
Micah Drayton
USPTO Deadlines
Next Deadline
880 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20220531)
Due Date
May 31, 2028
Grace Period Ends
November 30, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 20, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Apr 20, 2023 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Apr 20, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Apr 20, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 31, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 31, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 15, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 15, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 23, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 10, 2022 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Feb 8, 2022 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Feb 4, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 31, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 31, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 31, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 31, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 25, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 13, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 19, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of liquid formulations of proteins, antibodies, peptides, and other small molecules, and for use in evaluating their respective solubility properties, all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of nanoparticle formulations, including investigating parameters related to drug release, particle size, aggregations, and drug integrity, all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of vaccine stability formulations, all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of antibody conjugates and antibody drug conjugates (ADCs), all the foregoing using Design of Experiments Approach in a multivariate fashion; Pre-designed biochemical preparations for use in evaluating biopharmaceutical drug formulations in the nature of diagnostic reagents and for use in evaluating their stability and compatibility in various formulations with respect to the effect of pH, ionic strength, buffer and stability concentrations, all the foregoing using Design of Experiments Approach in a multivariate fashion
First Use Anywhere:
Jun 28, 2010
First Use in Commerce:
Jun 28, 2010
Class 042
Scientific research services related to providing an optimum process for identifying stable formulations for biotech drugs such as protein, peptides, and small molecules, using advanced Design of Experiments strategy; Scientific laboratory services related to providing an optimum process for identifying stable formulations for biotech drugs such as protein, peptides, and small molecules, using advanced Design of Experiments strategy
First Use Anywhere:
Mar 28, 2010
First Use in Commerce:
Jun 28, 2010
Additional Information
Pseudo Mark
I FORMULATE
Classification
International Classes
001
042